BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T052046
CREATED:20200422T133821Z
LAST-MODIFIED:20200605T111031Z
UID:25202-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:5th Probiotics & Prebiotics Congress: USA
DESCRIPTION:This Congress will include numerous presentations on probiotics discovery and product development\, as well as prebiotics\, diet and nutrition. Alongside several case studies on digestive health\, metabolic diseases\, ageing and allergy\, the conference highlighted the importance of the early life microbiome\, the milk microbiome\, and the use of probiotics to modulate the infant gut. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda. \n 
URL:https://www.pharmajournalist.com/event/5th-probiotics-prebiotics-congress-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T052046
CREATED:20200722T114844Z
LAST-MODIFIED:20200722T114844Z
UID:26443-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:3rd Annual Lab Asset & Facility Management in Pharma 2020
DESCRIPTION:The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM\, enabling you to regain control of your assets\, optimize your space and benchmark best practices to stay ahead of the curve. \n \nThrough strategic planning and rolling out digital tracking\, Lab Asset\, Operations and FM Directors are beginning to regain control of their inventory\, asset value and optimize facility footprint to: \n\nReduce unnecessary downtime and ensure reliable business operations\nStrengthen relationships and drive innovative partnership models with OEMs\nMaximize asset lifecycle and value – and make informed financial decisions during purchasing\, renewing\, reselling and auctioning\nOptimize lab and working space\, implementing the ethos of shared economy within the R&D scientific community\nEnhance capital efficiency to re-invest in drug development programs\nAnticipate expansion from a lab and equipment perspective
URL:https://www.pharmajournalist.com/event/3rd-annual-lab-asset-facility-management-in-pharma-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T052046
CREATED:20200727T160850Z
LAST-MODIFIED:20200727T160850Z
UID:26517-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:Digital Neuropsychiatric Drug Development Summit
DESCRIPTION:The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive\, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics. \n \nWith an emphasis on depressive disorders\, schizophrenia\, addiction and PTSD\, this timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nDive into novel therapeutic approaches for PTSD with Aptinyx\, Bionomics\, Tonix & MAPS\nUncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics\, NeuroRx & Intra-cellular Therapeutics\nExplore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis\, Otsuka & Yale University\nHear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA\nLearn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern\n\nUniting 60+ drug developers from all corners of the world\, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics. \nTo know more about Digital Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/digital-neuropsychiatric-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201114
DTSTAMP:20260515T052046
CREATED:20200818T085642Z
LAST-MODIFIED:20200818T090545Z
UID:26793-1604966400-1605311999@www.pharmajournalist.com
SUMMARY:TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:Europe’s #1 forum for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market\, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies\, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition\, and work towards collaborations.
URL:https://www.pharmajournalist.com/event/tides-europe-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201111
DTSTAMP:20260515T052046
CREATED:20200821T150457Z
LAST-MODIFIED:20200821T150457Z
UID:26819-1604966400-1605052799@www.pharmajournalist.com
SUMMARY:2nd Annual Biomarkers for Rare Non-Oncological Disorders
DESCRIPTION:The Digital 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma\, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology. \nThis event is completely free for Drug Developers\, Researchers and Academics. To register your complimentary pass\, simply follow this link: www.nononcologyraredisease-summit.com/take-part/register/ \nTackling critical challenges from early research through to late-stage market access\, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need. \n How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products? \n Drawing on a multitude of disease areas spanning neurology\, cardiology\, metabolic\, renal\, inflammatory and more\, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities. \nWith 2 days of in-depth case studies\, interactive panel discussions\, dedicated Q+A time and valuable networking opportunities\, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory\, payer and commercial discussions. \nTake a look at the full event guide to see all case studies\, pre-conference workshop details and the full expert speaker faculty!
URL:https://www.pharmajournalist.com/event/2nd-annual-biomarkers-for-rare-non-oncological-disorders/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201112
DTSTAMP:20260515T052046
CREATED:20201109T092141Z
LAST-MODIFIED:20201109T092440Z
UID:27850-1604966400-1605139199@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Skin 2020
DESCRIPTION:2019 proved to be a pivotal year for the skin microbiome\, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly\, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations. \n \nMoving forward into 2021\, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis\, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products. \nSo\, what’s different at Microbiome Connect: Skin EU Virtual? \nSix new topics to explore: \n\nThe skin-gut axis and the development of ingestible beauty products.\nPersonalisation of skin-microbiome products and formulation considerations.\nDefining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.\nNext generation sequencing techniques and their application in claims development.\nNew data demonstrating the role of the microbiome in common skin conditions including acne\, eczema and dandruff.\nThe vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.\n\nAll tickets to tune into this event are 2FOR1 – simply quote this when booking online!
URL:https://www.pharmajournalist.com/event/microbiome-connect-skin-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201111
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T052046
CREATED:20200908T143929Z
LAST-MODIFIED:20200908T143929Z
UID:26962-1605052800-1605225599@www.pharmajournalist.com
SUMMARY:2nd Digital Exosome Based Therapeutic Development Summit
DESCRIPTION:The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However\, more is needed to be done to uncover more scientific knowledge\, fine-tune manufacturing methods and prepare trials to meet regulatory expectations. \nConsidering this\, the 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12\, 2020) will unite pharma\, biotech\, academic and technology providers to advance exosome therapeutics into a clinical and commercial reality. \n \nThis is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutics. Bringing together industry leaders and newcomers on the field\, it’s two days not to be missed. \nWith 20+ speakers and 2 days of unrivalled in-depth content\, join your peers to discuss: \n\nEnd-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes\, clinical preparation\, commercial strategy and more with Evox Therapeutics\, Aruna Bio\, Codiak Biosciences and ReNeuron\nInnovations in exosome-based therapeutics\, such as their applications in COVID-19 vaccines with Capricor Therapeutics\nUnderstanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen\nPreparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics\nOver 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!\n\nIf you are exploring the therapeutic applications of exosomes in an evidence-based approach\, this is the place for you. \nSpanning 2 days\, this digital program is tailor-made to showcase the field’s most exciting breakthroughs to inform your discovery\, manufacturing\, commercial and regulatory strategies. Join this interactive forum this November to drive GMP-grade manufacturing methods\, consistent exosome production\, improved isolation and purification\, effective clinical and regulatory preparations\, beneficial industry partnerships and more. \nTo know more about 2nd Digital Exosome Based Therapeutic Development Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-digital-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201112
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T052046
CREATED:20201109T093155Z
LAST-MODIFIED:20201109T093155Z
UID:27859-1605139200-1605225599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Human 2020
DESCRIPTION:Microbiome Connect: Human EU has been postponed this year due to the impacts of COVID-19.  However\, at Microbiome Connect\, we’re committed to continue providing a platform for scientific presentations and networking opportunities for the microbiome community before we return to face-to-face again in 2021. \n \nThis November\, we’ll be running a free-to-attend virtual symposium highlighting some of the latest scientific activity. Tune in for free on 12th November\, 2020. \nAgenda: \n9.30 – 10:00 AM | Iron and the gut microbiome: an opportunity for LBPs functional during active gut inflammation\nJenny Bailey – CEO – Ferryx \n10.15 – 10:40 AM | Gut-Brain axis mechanism of action and Clinical results on Hafnia alvei HA4597\, a new probiotic strain for the regulation of appetite and weight management\nGregory Lambert – CEO – Targedys \n10:55 – 11:20 AM | Rationally Designed Probiotic\nDr. Olaf Larsen – Senior Manager Science – Yakult Nederland B.V. \nRegister for free online.
URL:https://www.pharmajournalist.com/event/microbiome-connect-human-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201118
DTSTAMP:20260515T052046
CREATED:20200422T134911Z
LAST-MODIFIED:20200422T134911Z
UID:25203-1605484800-1605657599@www.pharmajournalist.com
SUMMARY:4th Global Pharma R&D AI\, Data Science and Informatics Summit
DESCRIPTION:This Summit is designed to create a collaborative environment in which attendees engaged with the speakers\, sponsors and other delegates in attendance. The meeting agenda has expanded to include: \n\nAI for genomics\, single-cell analysis and target validation.\nAI for predicting patient response.\nAI impacting clinical trials.\nAI for imaging.\nAI for cancer immunotherapy and neurodegenerative diseases\,\nClinical informatics\, data integration\, management and storage\,\nDigital therapeutics\, wearables and sensors.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/4th-global-pharma-rd-ai-data-science-and-informatics-summit/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201118
DTSTAMP:20260515T052046
CREATED:20200423T105853Z
LAST-MODIFIED:20200423T105853Z
UID:25211-1605484800-1605657599@www.pharmajournalist.com
SUMMARY:5th Medicinal Chemistry & Protein Degradation Summit
DESCRIPTION:This Summit will focus its attention to some of the leading issues in Medicinal Chemistry today. This year the conference has expanded its coverage on protein degradation and will have a dedicated track running across both days to explore the cutting-edge research taking place in this exciting area.  \nThe integration of AI and machine learning into the medicinal chemistry process is tackled in another track at the meeting with numerous case studies into how this developing technology is being utilized by industry leaders including Exscientia\, Insitro and Bayer. This compliments the co-located informatics and AI meeting\, which can be attended at any time\, and examines artificial Intelligence in other parts of the drug discovery timeline. \nFinally\, the conference will be looking into recent advances and case studies in phenotypic screening and novel approaches to DNA encoded libraries within a dedicated track. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships.  \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/5th-medicinal-chemistry-protein-degradation-summit/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T052046
CREATED:20200826T130619Z
LAST-MODIFIED:20200826T130619Z
UID:26852-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:2nd Annual Proteome- Targeted Drug Discovery Summit – Digital Event
DESCRIPTION:With about 85% of the proteome currently undrugged\, accessing these targets that are\, at present\, extremely difficult to drug\, has prevented researchers from achieving desired clinical successes. \nThe 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech\, as well as key opinion leaders in academia\, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency\, selectivity\, and physio-chemical properties. \n \nJoin the leading experts from the biopharmaceutical industry and academia to enhance your existing structural\, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline. \nKey Reasons to Attend Include \n\nUtilize next-generation chemical biology platforms for novel target target identification with insights from Biogen\, Merck & AstraZeneca\nExpand the druggable proteome through next-generation screening platforms\, with insight from GSK\, PhoreMost & Ribon Therapeutics\nLeverage innovative chemical probes to accelerate fragment-based lead generation\, with insights from Novartis & The Weizmann Institute of Science\nHarness structure-based computational technologies to successfully target protein-protein interactions\, with insights from RAPT Therapeutics\nGive rise to novel therapeutic modalities to drug the undruggable\, with insights from Silicon Therapeutics& AbbVie\n\nTo know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-proteome-targeted-drug-discovery-summit-digital-event/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T052046
CREATED:20200917T132624Z
LAST-MODIFIED:20200917T132919Z
UID:27122-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:4th Annual Antifibrotic Drug Development Summit
DESCRIPTION:Solving the Translational Drug Development Gap\, From Fibrotic Mechanisms to Clinically Effective Therapeutics. \nNow in its 4th year\, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights\, AFDD will bridge the current translational gap to anti-fibrotic drug development success \nJoin 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs. \nTo know more about 4th Annual Antifibrotic Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-antifibrotic-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T052046
CREATED:20201021T154020Z
LAST-MODIFIED:20201022T115845Z
UID:27582-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:3rd Lifecycle Management for Combination Products Summit
DESCRIPTION:The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development\, to CMC and regulatory affairs\, our experts speakers will help you delve into how to produce a quality and safe combination product\, implications of EU MDR and the final implementation phase of post-market surveillance reporting. \nTo know more about 3rd Lifecycle Management for Combination Products Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-lifecycle-management-for-combination-products-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T052046
CREATED:20200910T131817Z
LAST-MODIFIED:20200917T152111Z
UID:26980-1605571200-1605743999@www.pharmajournalist.com
SUMMARY:Clinical Operations in Oncology Trials USA 2020: Virtual Conference
DESCRIPTION:As the industry grapples with unprecedented challenges\, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology\, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.\n\nTo know more about Clinical Operations in Oncology Trials USA 2020 please click here.
URL:https://www.pharmajournalist.com/event/clinical-operations-in-oncology-trials-usa-2020-virtual-conference/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201120
DTSTAMP:20260515T052046
CREATED:20200923T134148Z
LAST-MODIFIED:20200923T134148Z
UID:27221-1605571200-1605830399@www.pharmajournalist.com
SUMMARY:CRISPR 2.0
DESCRIPTION:Discover the Next Generation of CRISPR Tools to Enhance Specificity\, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality \nCRISPR is one of the most powerful discoveries of the last decade. \nIn a remarkably short space of time\, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox\, which leads to the question: what’s next? \nCRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology\, from the potential of prime editing through to epigenome editing to treat chronic pain. \nDon’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools. \nJoin us to usher in the next generation of safe\, targeted and effective genome editing. \nFor more information on the conference\, visit https://ter.li/ok8ifs \n“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman\, Past attendee\, CRISPR Event Series \n” I greatly enjoyed the diversity and topic coverage of the talks\, thanks for putting together an excellent program!” Christina Kolodzy\, Past attendee\, CRISPR Event Series \n “A high-quality worthwhile conference\, attended by first rate professionals. I learned more than I anticipated I would” Past attendee\, CRISPR Event Series
URL:https://www.pharmajournalist.com/event/crispr-2-0/
LOCATION:Digital Congress
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T052046
CREATED:20200930T094828Z
LAST-MODIFIED:20210118T080755Z
UID:27309-1605657600-1608335999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December\, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th\, allowing you to do business in China\, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nCPhI & P-MEC China Virtual Expo Connect\nA hybrid offline-2-online platform for global pharma professionals\nNov 18 – Dec 18\, 2020 \nTo know more about CPhI & P-MEC China Virtual Expo Connect please click here.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect/
LOCATION:Virtual Event powered by CPhI China & Pharmasources.com
CATEGORIES:e
ORGANIZER;CN="CPhI China & Pharmasources.com":MAILTO:yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T052046
CREATED:20200422T095652Z
LAST-MODIFIED:20200605T104633Z
UID:25145-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:Digital Pathology & AI Congress: USA
DESCRIPTION:This meeting has a reputation for providing an outstanding networking experience. Discover how to effectively harness gains such as reducing lab costs\, improving links with other laboratories and scientists\, and minimizing human error. \n \nTopics covered on the agenda include: \n\nHow AI is being applied to primary diagnosis and clinical research.\nAI for image analysis and advancements in imaging\nComputational pathology and AI\nImplementation: practicalities and costs\nPharma and industry case studies\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/digital-pathology-ai-congress-usa/
LOCATION:New York\, USA\, United States
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T052046
CREATED:20200423T110625Z
LAST-MODIFIED:20200423T110625Z
UID:25215-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:Women and Infant Health Microbiome Congress
DESCRIPTION:With dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/women-and-infant-health-microbiome-congress/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T052046
CREATED:20200731T092307Z
LAST-MODIFIED:20200731T092307Z
UID:26532-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:Digital Agenda Revealed: 9th HPAPI Summit
DESCRIPTION:As the world around us evolves\, we want to ensure we can still unite you and your peers in highly potent API development and manufacturing. \nWe are excited to have transformed the 9th HPAPI Summit into a fully digital meeting running on November 19-20.  \nThanks to our dedicated speakers\, we’re still able to deliver the high-quality content and networking opportunities that you need to advance your high potent strategy in your company\, from development to containment to EHS and outsourcing. \nAnd the best part? As a giving back to our long standing HPAPI community\, pharma\, biotech and academia can now register for free! \nSolution provider rate starts from $1\,259\, register by August 7 to save up to $280. \nDownload the new digital event program here. \nHere’s a glimpse at some of the expert speakers confirmed to present: \n\nChristopher Sears\, Senior Director\, CMC Tarveda Therapeutics\nCornelia Rudolph\, Clean Water DG Environment\, European Commission\nGraeme McKilligan\, Lead Senior GMDP Inspector\, MHRA\nMirjam Sax\, Principal Site Manager\, Genentech\nDave Eherts\, Vice President Global EHS\, Allergan\nAndrew Hopkins\, Director\, Operation Quality\, QA Audit & Compliance\, AbbVie\nJohn Roosa\, Director\, New Technology Development & Industrial Hygiene Engineer\, Merck\n\nOur bespoke virtual conference platform will allow you to network with industry colleagues\, evaluate new suppliers and the latest technology HPAPI containment and participate in live Q&A with speakers. For more details see here. \nWe hope to see you there!
URL:https://www.pharmajournalist.com/event/digital-agenda-revealed-9th-hpapi-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201119
DTEND;VALUE=DATE:20201121
DTSTAMP:20260515T052046
CREATED:20201008T102355Z
LAST-MODIFIED:20201008T102858Z
UID:27406-1605744000-1605916799@www.pharmajournalist.com
SUMMARY:In-House Impact: Life Sciences 2020 – Virtual Event
DESCRIPTION:Redefining In-House Counsel as Innovator & Strategic Partner\, Maximizing & Benchmarking Legal Business Value to Set the New Standard for Today’s Life Sciences Lawyer. \nIn-House Impact works because it connects you with the most forward-thinking legal leaders taking the most radical steps to maximize the business value they add as strategic business partners. \nWith thought-provoking case studies\, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers\, we guarantee that your time and your money are well spent. \nThis conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences. \nWe believe the traditional conference format is no longer fit for purpose\, so we started from scratch. \n \nHere’s how it works: \nWhen you look at the event agenda\, you will see three main types of sessions: \n\nDiscover sessions offer you the chance to hear the boldest legal leaders in Life Sciences sharing the stories of what they’re doing to maximize the impact of their team\nDevelop sessions provide you with the unique opportunity to have your burning questions answered in a room full of your peers and move beyond the ‘what’ and the ‘why’ to get to the ‘how’\nAction sessions divide the audience by same-level seniority\, and are designed to help you discuss challenges with peers\, and decide what you are going to change in order to add as much value to the business\n\nIn-House Impact: Life Sciences is a new event\, both designed by and for General Counsels of Life Sciences companies\, from smaller start-ups to large pharmaceuticals. \nFor more information visit https://ter.li/cata3o\, or contact the team via email at info@hansonwade.com.
URL:https://www.pharmajournalist.com/event/in-house-impact-life-sciences-2020-virtual-event/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201124
DTEND;VALUE=DATE:20201125
DTSTAMP:20260515T052046
CREATED:20200910T133510Z
LAST-MODIFIED:20200917T152233Z
UID:26983-1606176000-1606262399@www.pharmajournalist.com
SUMMARY:*NEW* Translating Documentation & Communication Clinical Research: Virtual Conference
DESCRIPTION:This one-day online event will deliver top-quality content and engagement covering all aspects of language operations for clinical research: clinical trial protocols\, informed consent\, site documents\, regulatory submissions and correspondence\, labeling\, IFUs\, patient correspondence\, and much more.\n \nTo know more about Translating Documentation & Communication Clinical Research please click here.
URL:https://www.pharmajournalist.com/event/new-translating-documentation-communication-clinical-research-virtual-conference/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201126
DTEND;VALUE=DATE:20201127
DTSTAMP:20260515T052046
CREATED:20201103T111452Z
LAST-MODIFIED:20201103T111452Z
UID:27752-1606348800-1606435199@www.pharmajournalist.com
SUMMARY:Cost-efficient and Green Manufacturing of Peptides thanks to Molecular Hiving™ Technology
DESCRIPTION:HOSTED BY: Bachem Group\nLED BY: Dr. Wolfgang Seufert\, Director Production III – Process Development\, Bachem \nBachem and Jitsubo CO.\, Ltd. recently announced the signature of an exclusive Licensing Agreement for Jitsubo’s Molecular Hiving™ Technology. Under the License agreement\, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ Technology and transfer these processes to Bachem. Bachem will further optimize\, scale up and produce for commercial applications. \n \nMolecular Hiving™ is a tag-assisted liquid-phase peptide synthesis technology developed by Professor Kazuhiro Chiba at Tokyo University of Technology and Agriculture. This technology uses a hydrophobic tag\, which is applied in the same way as the resin for solid-phase peptide synthesis (SPPS) processes. The same standard Fmoc amino acid derivatives as for SPPS are applied for assembling the peptide chain. However\, all couplings and cleavages of the Fmoc protecting group are performed in solution allowing for fast reactions and direct in-process controls\, e.g. by HPLC. Excess reagents as well as coupling and cleavage related by-products are solely removed by aqueous extractions. Therefore\, intermediate isolation of the tag-bound peptide and excessive washing steps are not required for Molecular Hiving™ Technology. \nIn this webinar\, the speaker will guide you through the individual steps for synthesis of peptides applying Molecular Hiving™ Technology. You will learn about the scalability and the substantial advantages of this technology regarding efficiency and towards greener manufacturing\, as solvent consumption and material requirements are significantly reduced compared to conventional SPPS processes. Molecular Hiving™ also allows the synthesis of peptides without the use of solvents and reagents which are carcinogenic\, mutagenic\, or toxic to reproduction (CMR substances). This makes peptide products manufactured by this technology highly attractive for the pharmaceutical and cosmetics industry. \nBenefits for Joining the Webinar: \n\nHear about Bachem’s partnership with Jitsubo\nDiscover how to synthesize peptides by Molecular Hiving™ Technology\nExplore the advantages and the environmental benefits of Molecular Hiving™ Technology\nLearn about manufacture of peptides without CMR solvents and reagents\n\nWho should attend? \nScientists in Pharma\, Biotech\, Cosmetics industry\, and Universities including: \n\nResearch Scientists and Associates\nPostDocs and PhDs\nScientific Advisors\nDirectors of Research and Development\n\nOther Professionals in the Life Sciences including Product Managers and Marketing Managers
URL:https://www.pharmajournalist.com/event/cost-efficient-and-green-manufacturing-of-peptides-thanks-to-molecular-hiving-technology/
LOCATION:Online Webinar
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201130
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T052046
CREATED:20200715T082010Z
LAST-MODIFIED:20200817T082502Z
UID:26329-1606694400-1607039999@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Analytical Development | Running Digitally for 2020
DESCRIPTION:Optimizing Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of rapid gene therapy progress and mounting regulatory scrutiny\, the 2nd Annual Gene Therapy Analytical Development Summit will virtually unite large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific conference will unite the Analytical Development\, QC\, CMC\, and Process Development leaders grappling with these challenges first-hand. \nIncorporating tracks taking a deep dive into bioassays\, molecular biology\, and analytical chemistry\, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you’re encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo know more about 2nd Annual Gene Therapy Analytical Development please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-analytical-development/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T052046
CREATED:20200826T084509Z
LAST-MODIFIED:20200826T093822Z
UID:26843-1606780800-1607039999@www.pharmajournalist.com
SUMMARY:2nd RNA Editing Summit 2020
DESCRIPTION:RNA Editing is reaching an inflection point and is rapidly being discussed\, invested in and adopted by the industry. \nThis year\, in an all new digital format\, the timely 2nd RNA Editing Summit returns as the only industry led meeting showcasing the recent developments of RNA editing mechanisms and dedicated to realizing the research and therapeutic opportunity of RNA editing as quickly as possible. \n \nThis meeting offers a wealth of relevant content covering everything from basic RNA biology and the fundamentals of RNA editing through to mitigating against off target activity to the plethora of clinical applications. \nJoin industry leaders from the likes of InsideOutBio\, Edigene\, Locano Bio and more to: \n\nHear the current strategies of site directed RNA editing from A – I to C – U to CRISPR based\nUnderstand how to mitigate off target-activity without critically effecting the efficiency of the on target edit in the transcript\nEnsure the safety and stability of your edit whilst maintaining efficiency and safe guard against potential toxic events\nAssess how to develop RNA editing technologies in preclinical models to ensure the system works as intended in the human body\nDelve into the different delivery mechanisms available to ensure the protein molecules that do the editing make it into the cells\nIdentify the latest clinical applications of RNA Editing\, reviewing the structures and functions of ADARs\, CRISPR CAS 13\, APOBEC and their involvements in human diseases\n\nTo know more about 2nd RNA Editing Summit 2020 please click here.
URL:https://www.pharmajournalist.com/event/2nd-rna-editing-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201203
DTSTAMP:20260515T052046
CREATED:20200930T082606Z
LAST-MODIFIED:20200930T082606Z
UID:27304-1606780800-1606953599@www.pharmajournalist.com
SUMMARY:Neuromuscular Drug Development Summit
DESCRIPTION:Validate Clinically Meaningful Endpoints\, Optimize Clinical Trial Design & Compare & Contrast Diverse Approaches to Accelerate the Discovery & Development of Meaningful Treatments for Patients in Need \n \nThe 3rd Neuromuscular Drug Development  Summit presents a unique opportunity to: \n\nUncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen\nHear approaches to optimizing therapeutic efficacy in SMA\, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche\, PTC Therapeutics and John Hopkins University School of Medicine\nAssess emerging neurophysiological methods for more quantitative\, faster readouts and the need to explore digital capture tools to improve therapeutic R&D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD)\nDissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose\, mechanisms of action and endpoints with NMD Pharma and Argenx\nEvaluate the role of biomarkers\, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institut\nHear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1\n\nUniting drug developers and academics from all corners of the world\, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field\, convey lessons learned and network to build long lasting partnerships.
URL:https://www.pharmajournalist.com/event/neuromuscular-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T052046
CREATED:20200423T111553Z
LAST-MODIFIED:20200423T111553Z
UID:25220-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:7th Microbiome & Probiotics R&D & Business Collaboration Forum: Europe
DESCRIPTION:In response to COVID-19\, this meeting will be hosted online using the latest digital technology. Network with your peers\, ask questions of the speakers\, and meet with the sponsors from the safety of your home or office. \nThis forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products. \nTopics covered on the agenda include: \n\nIBD\, Colitis\, and Metabolic Diseases\nGut-brain axis\nWomen’s health\nSkin & Cosmeceuticals\nPersonalized nutrition\nBusiness Collaboration – Regulations & Investment\nProbiotics & Prebiotics\nRoundtable discussions\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-microbiome-probiotics-rd-business-collaboration-forum-europe/
LOCATION:Rotterdam\, The Netherlands
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T052046
CREATED:20200828T083254Z
LAST-MODIFIED:20200828T083616Z
UID:26875-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:Clinically Validated Digital Therapeutics Summit
DESCRIPTION:As the world opens up to digital health\, now is the time to design\, develop & deliver clinically validated digital therapeutics to patients in need. Back for its 3rd year\, the Clinically Validated Digital Therapeutics Summit will unite more stakeholders than ever before. Explore newcomers in the world of DTx\, showcasing never before shared case studies. This meeting will solely focus on the actionable uses of digital therapeutics to deliver radically improved patient outcomes. \nIntegrating brand new lessons learned from the COVID 19 pandemic\, the 2020 summit will drive the DTx industry forward with case studies that tackle a multitude of disease areas and therapeutic modalities\, from prescription and chronic disease management to care bundles\, concomitant therapy and preventive medicine. Covering the full spectrum\, the 2020 summit will address challenges around clinical trials\, regulatory approval\, reimbursement and value application in healthcare. \nView the Full Event Guide Here.
URL:https://www.pharmajournalist.com/event/clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201203
DTEND;VALUE=DATE:20201205
DTSTAMP:20260515T052046
CREATED:20200423T112329Z
LAST-MODIFIED:20200605T110454Z
UID:25224-1606953600-1607126399@www.pharmajournalist.com
SUMMARY:7th Digital Pathology & AI Congress: Europe
DESCRIPTION:This meeting has a reputation for providing an outstanding networking experience in which you can discover how to effectively harness gains such as reducing lab costs\, improving links between other laboratories & scientists and minimizing human error. \n \nOver two days you will discover more about the latest advances and applications of digital pathology\, including: \n\nHow artificial intelligence and machine learning is being applied to primary diagnosis and clinical research.\nHow the image-based information environment is transforming the laboratory.\nAI for image analysis and advancements in imaging.\nComputational pathology and AI.\nImplementation: practicalities and costs.\nPharma and industry case studies.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-digital-pathology-ai-congress-europe/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201207
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T052046
CREATED:20200217T121202Z
LAST-MODIFIED:20201123T131643Z
UID:24217-1607299200-1607644799@www.pharmajournalist.com
SUMMARY:BioFIT 2020
DESCRIPTION:Come and join us online for the 9th edition of BioFIT\, from the 7th to the 10th of December 2020! \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \n \nKEY FIGURES: \n\n1\,400+ delegates\n900+ organisations\n40+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\nConferences and roundtable discussions\nOral presentations of start-ups and licensing opportunities stemming from academia\nAn exhibition area\nInformal networking evenings\n\nAcross these 4 days of event\, you will be able to e-meet and network with these attendees from the comfort of your home office. The one-to-one partnering meetings will be possible 24H a day. \nYou will also have access\, for the conferences and the pitch sessions\, to a mix of live and on-demand content during those 4 days and available for 30 days afterwards; and you will also have the opportunity to debate with the speakers and pitchers via interactive online chats. \nWebsite: www.biofit-event.com \nRegistration: www.biofit-event.com/registration-for-biofit/ \nContact: msatola@eurasante.com
URL:https://www.pharmajournalist.com/event/biofit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Eurasant%C3%A9%2C Clubster NHL%2C BioValley France and Eurobiomed":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201208
DTEND;VALUE=DATE:20201211
DTSTAMP:20260515T052046
CREATED:20200817T090658Z
LAST-MODIFIED:20200817T090658Z
UID:26779-1607385600-1607644799@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy for Neurological Disorders | Running Digitally for 2020
DESCRIPTION:Revolutionize the Development & Delivery of Neurological Gene Therapies  \nReturning this year as a digital meeting with an agenda designed with the field’s thought-leaders including Pfizer\, Biogen\, Voyager and Novartis\, the 2nd Annual Gene Therapy for Neurological Disorders is the industry’s only meeting dedicated to solving your translational drug development challenges\, enabling you to accelerate the development of your neurological gene therapy candidate. \nDon’t get left behind. Attend this meeting to transform gene therapy delivery to the CNS\, optimize translational modelling approaches and discover targeted\, efficacious\, and safe vectors to revolutionize the treatment of neurological disorders. \nTo learn more about Gene Therapy for Neurological Disorders please click here: https://ter.li/c610sy
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-for-neurological-disorders-running-digitally-for-2020/
LOCATION:Vitual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR